1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
64155530F062E1B860025863F0071CBD6
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/patient-advocacy-internal-collaboration-partnerships-R&D-policy-access?opendocument
18
19opendocument
203.232.96.22
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Patient Focused Services Patient Advocacy Groups

Patient Advocacy Internal Collaboration: Partnerships with R&D, Policy and Access

ID: 5657


Features:

9 Info Graphics

16 Data Graphics

100+ Metrics

10 Narratives


Pages/Slides: 30


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Patient Advocacy Internal Collaboration: Partnerships with R&D, Policy and Access"

STUDY OVERVIEW

Creating and maintaining a patient-centric biopharmaceutical organization requires not just the influence of an Advocacy Team but the influence of all other parts of the organization. This study examines how advocacy teams can improve coordination efforts with internal groups such as Marketing, Medical Affairs, R&D, and Government Affairs.

In particuar, this study spotlights R&D Partnerships with Patient Advocacy Groups;Transforming Policy and Access with Patient Advocacy Groups;and Best Practices in Leveraging Internal Patient Advocacy Interactions. Advocacy leaders can use this research to improve its collaborative efforts with internal stakeholders regarding these topics.

KEY TOPICS

  • R&D Partnerships with Advocacy
  • Advocacy Role in R&D
  • Policy and Access Partnerships
  • Legal and Compliance Involvement in Advocacy Activities
  • Transparency of Financial Partnerships

KEY METRICS
  • Impact of patient advocacy team’s effort on guiding research and development
  • Benchmark partners’ narratives around successful collaboration with the R&D function around patient advocacy to impact the lives of patients
  • Roles fulfilled by internal advocacy teams when partnering with the R&D group
  • Types of data collected by advocacy teams from patient advocacy groups to inform R&D
  • Benchmark participants’ partnership success stories
  • Benchmark partner’s narrative around successful collaboration with the clinical team
  • Legal and Compliance Involvement in Advocacy Activities
  • Legal’s / compliance’s guidelines when reviewing communications and submissions to patient advocacy groups
  • Impact of patient involvement with the FDA
  • Effectiveness of partnerships with Government Affairs in changing government policy to improve access to medications
  • Legal and compliance involvement in patient advocacy activities
  • Disclosure of financial data on advocacy teams’ contributions to patient advocacy groups
SAMPLE KEY FINDINGS
  • Clear Rules of Engagement Boost Government Affairs Collaboration: Highly effective groups are letting Government Affairs take the lead on policy but also setting clear rules of engagement to avoid legal issues

METHODOLOGY

This study engaged 54 leaders from 44 biopharma organizations via a benchmark survey.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Communications; Biopharmaceutical; Health Care; Energy; Chemical


Companies Profiled:
AbbVie; Bayer; Astellas; Alexion Pharmaceuticals; ApotheCom; Arena Pharmaceuticals; Bluebird Bio; Boehringer Ingelheim; Clovis Oncology; Dermira; Eli Lilly; Forma Therapeutics; Johnson & Johnson; Galapagos; Horizon Therapeutics; Ipsen; Kiniksa Pharmaceuticals; Milestone Pharmaceuticals; Myovant Sciences; Amicus Therapeutics; NexGen Healthcare Communications; Novartis; Novo Nordisk; Orchard Therapeutics; Orion Energy; Genentech; Roche; OTSUKA; Reata Pharmaceuticals; Sangamo Therapeutics; Spark Therapeutics; Sunovion; Syneos Health; Takeda Pharmaceuticals; TG Therapeutics; Theravance; UCB Pharma; United Therapeutics; Wave Life Sciences; Zogenix; Vifor Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.